Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

NCT06873100

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Peking University People's Hospital
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Male or female e18 and d70 years
- Meet the revised Michet criteria
- Patients had an inadequate response to standard treatment for e 4 weeks. The background treatment included corticosteroids (d0.5 mg/ kg), immunosuppressants (methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil leflunomide, or cyclophosphamide)
- \. Negative urine pregnancy test
- \. Written informed consent form

Exclusion (13)

- Any subject who meets any of the following criteria shall be excluded:
- Use rituximab or other monoclonal antibodies within 2 months.
- months after treatment with high dose glucocorticoid (\> 1 mg/kg/d).
- Serious complications: heart failure (e New York Heart Association NYHA III grade), renal insufficiency (creatinine clearance rate d 30 ml/min), liver function insufficiency (serum alanine transaminase or glutamic-pyruvic transaminaseT \> 3 times normal upper limit, or total bilirubin \> normal upper limit)
- Other serious, progressive or uncontrollable hematological, gastrointestinal, endocrine, lung, heart, nerve, or brain diseases (including demyelination diseases, such as multiple sclerosis).

... and 8 more (see full listing online)

Locations (1 total)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing Municipality, China